Objectives. We sought to assess the incidence and clinical relevance of examination data to recurrent ischemia within an international randomized trial.
In-hospital recurrent ischemia after acute myocardial infarction (MI) has been recognized for years as a marker of both death and reinfarction (1) (2) (3) (4) (5) (6) (7) . In practice, most patients do not undergo special monitoring to detect ischemia; only when ischemic symptoms occur are symptom assessment, physical examination and electrocardiography (ECG) performed. The relevance of the various clinical and ECG findings during an episode of postinfarction angina remains to be elucidated. In addition, although the outcome of patients presenting with myocardial ischemia after MI may not be changed by previous thrombolysis (8 -13) , no large study has prospectively assessed the incidence and clinical implications of symptoms compatible with recurrent ischemia in the thrombolytic era. We analyzed, as part of the Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries (GUSTO-I) trial, the incidence of the examination data collected during recurrent ischemia and evaluated their relation to clinical outcomes.
thereafter. Patients with no contraindication were to receive intravenous atenolol on entry, followed by daily oral therapy. All other medications were prescribed at the discretion of the attending physician.
Data collection and study design. Baseline clinical variables were collected for all patients with standard data collection forms. Quality control was checked at data entry, and missing or questionable answers were queried. A sample of 12% of the forms was audited by comparing data on the form with the hospital medical record.
Investigators were to record the date and time of the first episode of recurrent ischemia, defined as the first appearance of symptoms (such as chest, arm or jaw pain; nausea; and others) or signs (ECG changes or new sustained hypotension [systolic blood pressure Ͻ90 mm Hg, or Ͼ30 mm Hg less than the previous measure, for Ͼ1 h, despite fluid administration], pulmonary edema or a murmur thought by the clinician to represent ischemia). When such symptoms or signs occurred, the following variables were recorded: ST segment deviation from baseline, presence of pulmonary rales, third sound gallop and hypotension. Data on recurrent ischemia were lacking for 173 of the 41,021 patients in GUSTO-I.
The patient was then categorized into one of five groups. Group 1 included patients with no signs or symptoms (as just listed) of recurrent ischemia; Group 2, patients with angina but without documented ST segment changes or hemodynamic abnormalities; Group 3, patients with angina and ST segment changes but without hemodynamic abnormalities; Group 4, patients with angina and hemodynamic abnormalities but without documented ST segment changes; and Group 5, patients with angina, ST segment changes and hemodynamic abnormalities. These categories are in keeping with the recommendations of the Agency for Health Care Policy and Research (AHCPR) (15) for the management of patients with unstable angina, which emphasize the importance of risk stratification based on clinical presentation, ECG findings and physical examination data.
End points and definitions. Prospectively defined end points were 30-day mortality, reinfarction, cardiogenic shock, use of angioplasty or bypass surgery and length of hospital stay. Reinfarction was diagnosed by the presence of at least two of the following four criteria: 1) ischemic symptoms lasting Ͼ15 min occurring after resolution of symptoms of the index infarction; 2) occurrence of new ST-T wave changes or new Q waves; 3) reelevation in cardiac enzymes above the normal upper limit (or by another 20% if already above the normal upper limit); or 4) angiographic reocclusion of an infarctrelated artery previously patent. Definition of shock included systolic blood pressure Ͻ90 mm Hg for Ͼ1 h that was unresponsive to fluid administration, considered secondary to cardiac dysfunction and associated with signs of hypoperfusion (cool, clammy skin, oliguria or altered sensorium) or cardiac index Յ2.2 liters/min per m 2 ; if the patient presented with cardiogenic shock at enrollment, that episode did not count for this end point.
Statistical analysis. Baseline characteristics and clinical outcomes are presented as percentages for binary variables and medians with 25th and 75th percentiles for continuous characteristics. Statistical testing was confined to analyses of whether a significant association was present for each characteristic such that a greater proportion of patients with the outcome of interest was found in groups with greater findings of ischemia than in groups with lesser findings of ischemia. Because of the multiple possible comparisons, specific testing of the significance of differences between individual groups was avoided. For the GUSTO-I trial as a whole, when comparing patients with and without recurrent ischemia, for example, any differences Ͼ1% in baseline characteristics or outcomes would have a nominal p value Ͻ 0.001.
Selected baseline characteristics and clinical outcomes were compared among the five groups by chi-square tests for discrete variables and by nonparametric analysis of variance (Kruskal-Wallis) for continuous variables. Kaplan-Meier estimates were calculated for 30-day and 1-year survival and time to reinfarction for each recurrent ischemia category.
Results
A total of 40,848 patients had data available for review. Symptoms of possible recurrent ischemia occurred in 8,131 (20%) of the study patients (Groups 2 to 5, Table 1 ). Patients with recurrent ischemia were more likely to be female, hypertensive and hypercholesterolemic, and they more often had prior angina and prior MI than those without recurrent ischemia. In general, baseline factors associated with mortality were more prevalent in patients who later had more severe clinical manifestations of recurrent ischemia.
No major differences were found among the five groups with respect to assigned thrombolytic agent and time to thrombolytic treatment (Table 2) . However, patients with recurrent ischemic symptoms received intravenous heparin less often, and for a shorter duration, than those without symptoms. Activated partial thromboplastin time (aPTT) values at 24 h were slightly but statistically significantly higher in patients with recurrent ischemia.
Although beta-adrenergic blocking agents were given equally among the five groups, patients with recurrent ischemia received nitrates, calcium channel antagonists, digitalis and angiotensin-converting enzyme (ACE) inhibitors more often than those without symptoms ( Table 2 ). The use of diagnostic and therapeutic procedures, including angioplasty and coronary artery bypass surgery, increased as a function of ST segment changes and hemodynamic impairment. Angiography (Table 3 ) was performed more often in patients with symptoms of recurrent ischemia, and it was more often done on an emergency basis in these groups. Reperfusion of the infarct-related coronary artery (Thrombolysis in Myocardial Infarction [TIMI] grade 3 blood flow) was more prevalent in patients without recurrent symptoms of ischemia, whereas more severe stenoses, triple-vessel disease and lower ejection fractions were observed in the recurrent ischemia groups, with a greater frequency of markers of more severe disease present in patients with more severe manifestations of ischemia.
Clinical events are listed in Table 4 . The median time to onset of recurrent ischemia was 1.5 days. Again, worse outcomes and longer hospital stays paralleled the severity of recurrent ischemia. In patients who had a reinfarction, the reinfarction tended to occur simultaneously with recurrent ischemia. Among patients who died, death tended to occur shortly after the recurrent ischemia when the recurrent ischemic event was accompanied by hemodynamic abnormalities, whereas death most often occurred several days later in patients with recurrent ischemia without evidence of hemodynamic distress. Mortality at 30 days did not appear to increase in patients whose angina was not accompanied by hemodynamic impairment (Groups 2 and 3), but it was dramatically higher in the presence of signs of heart failure (Groups 4 and 5). This is well illustrated in Figure 1A , where the KaplanMeier survival curves for Groups 1, 2 and 3 appear similar, with mortality rates of 6.6%, 5.4%, and 7.7%, respectively, at 30 days, and are significantly lower than those of Groups 4 and 5 (21.8% and 29.1%, respectively). Figure 1B shows that this pattern was maintained at 1 year. In contrast, the rate of reinfarction, increased with the mere presence of angina and was even higher with concomitant ECG changes, hemodynamic impairment, or both. The corresponding Kaplan-Meier curves are depicted in Figure 2 . Data presented are median (25th, 75th percentiles) or number (%) of patient group. CAD ϭ coronary artery disease; CK ϭ creatine kinase; Group 1 ϭ patients without signs or symptoms of recurrent ischemia; Group 2 ϭ patients with angina only; Group 3 ϭ patients with angina and ST segment changes; Group 4 ϭ patients with angina and hemodynamic abnormalities; Group 5 ϭ patients with angina, ST segment changes and hemodynamic abnormalities.
Discussion
The reported incidence of recurrent ischemia after MI varies considerably, ranging from 6% to 50% in representative series of patients who did not receive thrombolytic treatment (1-6,9 -12) . The large Multicenter Postinfarction Research Trial (16) and the Perth Coronary Registry (17) reported an incidence of 33% and 38%, respectively. The wide variation of these figures might be explained by differences in both the clinical characteristics of the study patients and the diagnostic criteria used. For example, the lowest incidence corresponds to a study limited to patients with Q wave MI (5), whereas the highest relates to patients presenting with non-Q wave MI (18, 19) . Similarly, some studies have considered recurrent ischemia after a first MI only (7), whereas most series have included recurrence after any MI. In addition, the number of episodes of chest pain required to qualify (20, 21) , the severity of these episodes (22) , the need for concurrent ECG changes (1,2,5,23) and the time window chosen (21) are not uniform among the different studies.
Another critical issue in understanding the incidence of recurrent ischemia is the technology used to define its presence. In a recent study of 406 postinfarction patients (24), many of whom did not receive thrombolytic therapy, 23% had recurrent angina and 23% had ischemia diagnosed within 48 h of admission by continuous ambulatory ECG monitoring. Given that many asymptomatic episodes of ambulatory ischemia occurred and that monitoring continued for only 48 h, continuous monitoring for a longer period would more likely have found greater evidence of ischemia. Similarly, in a subset of the GUSTO-I patients, Langer and colleagues (25) found a high incidence of recurrent ischemia in the first 48 h.
Patients successfully treated by thrombolytic therapy may be at increased risk for postinfarction angina (8, 26) , although studies have produced conflicting results (9, 12) . In the study by Campolo and colleagues (4), in which many patients underwent thrombolysis, the incidence of postinfarction angina was 26%. Silva and colleagues (27) found early recurrent ischemia, defined by spontaneous chest pain and ST-T wave changes, to be present in 35 (8%) of 453 low risk patients after the first 24 h of an uncomplicated course after thrombolysis. A recent review of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) series (13) found an 18.3% incidence of recurrent ischemia, defined by symptoms and associated ECG changes. Stone and colleagues (28) noted a higher incidence, Data presented are median (25th, 75th percentiles) or number (%) of patient group. ACE ϭ angiotensin-converting enzyme; aPTT ϭ activated partial thromboplastin time; iv ϭ intravenous; sc ϭ subcutaneous; SK ϭ streptokinase; t-PA ϭ tissue-type plasminogen activator. Groups as defined in Table 1. 28% (56 of 200 patients treated with alteplase), despite the use of stringent criteria to define recurrent ischemia: chest pain for Ͼ20 min and ECG changes or new onset pulmonary edema, holosystolic murmur or hypotension. The incidence in the present study (20% [8% when the definition includes only ECG changes]) does not support the hypothesis that recurrent ischemia is more common in patients who undergo thrombolysis, at least not when heparin is given (as in GUSTO-I). However, the protocol called for the use of intravenous and oral beta-blockers (29) , which might well have prevented recurrent ischemia. In contrast, the thrombolytic agent given did not play a significant role in the occurrence of postinfarction angina.
Clinical and angiographic profiles of patients with recurrent ischemia. Age, preinfarction angina, lower creatine kinase (CK) values, and non-Q wave MI have been shown to be independent predictors of postinfarction ischemia (1,7,30 -34) . In particular, the importance of antecedent angina as a predictor of worse outcomes after thrombolysis has recently been stressed (35) . In keeping with these data are our findings of an association between advanced age and a higher prevalence of prior angina in the recurrent ischemia groups. In contrast, we did not observe lower CK-MB values in these subsets; indeed, peak total CK and peak CK-MB values were higher in the presence of hemodynamic impairment. This is probably to be expected, however, because our study did not exclusively enroll patients with non-Q wave MI, who presumably have less extensive tissue necrosis and more ischemic, but not infarcted, myocardium (20, 36, 37) .
From the angiographic standpoint, recurrent ischemia has been related to the extent and severity of coronary artery disease (1-3,7,31,38 -40) . Although these data have generally been derived from smaller series, they do not differ from our findings. Along with the higher prevalence of triple-vessel disease and more severe stenoses, we observed lower rates of TIMI grade 3 blood flow, always as a function of the severity of recurrent ischemia. In judging these results, however, one should consider that clinical indications led to appropriately different rates of angiography among the study groups (51% in patients without recurrent ischemia to 80% in those with ischemia and ECG changes), for both elective (78% in Group 1 vs. 41% in Group 5) and emergency (10% vs. 53%) catheterizations. Indeed, the absence of angiography in 20% of patients with recurrent ischemia raises questions about whether closer adherence to guidelines for angiography is needed. In a detailed analysis of the use of angiography in GUSTO-I, Pilote and colleagues (41) showed that age is the primary criterion for angiography, with recurrent ischemia a distant second.
Given the low sensitivity and specificity of coronary angiography to detect thrombus (42, 43) , its presence was not assessed systematically in this nonmechanistic study. Recently, coronary angioscopy performed in patients with recent MI identified coronary thrombus in all 17 patients with postinfarction angina but in only 5 of 34 without angina (44). Data presented are median (25th, 75th percentiles) or number (%) of patient group. LAD ϭ left anterior descending coronary artery; LCx ϭ left circumflex coronary artery; LMCA ϭ left main coronary artery; LV ϭ left ventricular; RCA ϭ right coronary artery; TIMI ϭ Thrombolysis in Myocardial Infarction. Groups as defined in Table 1 .
Patients with recurrent ischemic symptoms received intravenous heparin less often and for a shorter time, suggesting that intracoronary thrombus, platelet aggregation, or both, may play a role in the pathophysiology of postinfarction angina. However, the heparin data are confounded by uncertainty about why the heparin may have been discontinued early in each case. In some cases recurrent ischemia may have occurred after heparin was discontinued early because of bleeding or thrombocytopenia. Randomized trials of heparin therapy have shown a reduction in MI (45) and recurrent ischemia (46) , although the duration of this benefit is controversial (47) .
Clinical outcomes: the continuum of risk. Most studies have shown a definite prognostic value of early postinfarction angina with regard to mortality (from 17% to 56% at 1 year) and reinfarction (10% to 33%) (1) (2) (3) (4) (5) (6) (7) 18, 48) . Again, differences in the study patients and the inclusion criteria may account for the variation. When accompanying ECG changes are not required to qualify for the study, differences in mortality between patients with and without early postinfarction angina may vanish (48, 49) . Despite that background, however, little attention has been paid to the comparison of outcomes of patients with postinfarction angina who present with or without transient ischemic ECG changes. In the study by Bosch and colleagues (50) , which specifically addressed this issue, the probability of survival or survival without reinfarction of patients with angina but no ST segment changes approached that of patients without postinfarction angina and was significantly better than that of patients whose angina was accompanied by ECG changes. Nevertheless, the use of revascularization procedures was higher in the subset of patients with angina alone than in patients with no recurrent chest pain, and the investigators concluded that patients with angina and no ECG changes constitute-in terms of risk-an intermediate group between the patients without angina and those with angina and transient ECG changes. Furthermore, in the present study some ECGs were obtained promptly with no evidence of a change, whereas in other cases they were simply not obtained; thus, Group 2 may contain two populations with different prognoses.
Recently, the AHCPR (15) published clinical practice guidelines for the treatment of unstable angina. Three categories of risk were defined, in which patients with prolonged angina, those with dynamic ST segment changes and those with (8, 17) 11 (7, 15) 11 (6, 17) *All outcomes and events are in-hospital data except 30-day and 1-year mortality. †Kaplan-Meier estimates. Data presented are median (25th, 75th percentiles) or number (%) of patient group. CHF ϭ congestive heart failure. Groups as defined in Table 1. any evidence of acute heart failure were classified in the high risk group. This classification, predominantly describing unstable angina in the absence of a recent MI, recognizes the additional prognostic value of transient ECG changes. However, few data have been published on the role of ischemic symptoms accompanied by hemodynamic deterioration. Our observations show that with a simple evaluation, including symptom assessment, physical examination and ECG, a continuum of risk can be established for patients with recurrent angina after thrombolysis for acute MI. Furthermore, the risk gradient was not uniform across the five groups; some signs and symptoms were associated with a very high risk. Thus, although mortality increased substantially only in the presence of hemodynamic impairment, the risk of reinfarction rose with angina alone (and rose still further with accompanying ECG changes).
Limitations of the study. The present series illustrates that Ͼ50% of patients with recurrent ischemia do not show accompanying ECG changes. This finding implies that in the corresponding patient subset (Group 2), the diagnosis was made on clinical grounds. Other than the ECG, no procedures such as echocardiography or scintigraphy were routinely carried out to confirm ischemia. Nevertheless, angina pectoris remains a clinical diagnosis, based on the characteristics of the symptoms. Although particular attention was paid to exclusion of all other causes of nonischemic pain, identification of the exact nature of an episode of chest discomfort is often not easy; thus, the possibility of an incorrect diagnosis in individual patients cannot be ruled out. However, the results of the study remain relevant because the occurrence of chest pain (regardless of etiology) places the patient in a higher risk category.
Despite the size of the study group, the relative prognostic values of the various components of the hemodynamic abnormalities (pulmonary rales, third sound gallop and hypotension) were not separately analyzed, given the small number of patients included in Group 4. Finally, the prognostic implications of silent ischemia were not elucidated in our series. Although ambulatory ECG may provide prognostic information beyond that from standard clinical variables (24) , continuous recording was not performed in this large study; thus, the category of patients with ECG changes but no angina could not be evaluated.
Clinical implications. Symptoms of recurrent ischemia after MI remain frequent in the thrombolytic era, occurring in one of five patients despite the liberal use of heparin, beta-blockers and aspirin. Patients presenting with recurrent ischemia fall along a continuum of risk for negative outcomes as a function of ECG changes and hemodynamic burden. Angina alone does not seem to increase the shortor long-term risk of death, but it constitutes a marker of reinfarction and use of revascularization procedures. Although the risk of reinfarction is further increased by concurrent ECG changes, our findings reinforce the value of careful clinical evaluation. Death and cardiogenic shock are increased when hemodynamic abnormalities are present. Emphasis should be placed on prompt ECG and physical examination when symptomatic ischemia occurs, and appropriate management strategies should be based on the severity of risk as assessed during the period of acute ischemia, as well as on the coronary anatomy, left ventricular function and other associated conditions. 
